vTv Therapeutics Inc. (VTVT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.3450

+0.0550

(+4.26%)

As of 01:02PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	1.2900
Open	1.2900
Bid	1.3300 x 1300
Ask	1.3500 x 1100
Day's Range	1.2900 - 1.4000
52 Week Range	0.3820 - 2.1700
Volume	283,795
Avg. Volume	958,364

Market Cap	104.008M
Beta (5Y Monthly)	-1.37
PE Ratio (TTM)	N/A
EPS (TTM)	-0.2490
Earnings Date	Aug 15, 2022 - Aug 22, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	4.17

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VTVT

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

vTv Therapeutics Inc.
Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Rating
Fair Value
Economic Moat
11 days agoMorningstar

All

Simply Wall St.
What You Need To Know About vTv Therapeutics Inc.'s (NASDAQ:VTVT) Investor Composition
A look at the shareholders of vTv Therapeutics Inc. ( NASDAQ:VTVT ) can tell us which group is most powerful. Large...
- Are Institutions Heavily Invested In Starwood Property Trust, Inc.'s (NYSE:STWD) Shares?
  Simply Wall St.
- Is J.W. Mays, Inc.'s (NASDAQ:MAYS) Shareholder Ownership Skewed Towards Insiders?
  Simply Wall St.
American City Business Journals
Months after celebrating its first exit, CinRx invests $10M in newest portfolio company
A Cincinnati-based portfolio company that celebrated a massive exit earlier this year has invested millions to accelerate development of a new treatment option for people with Type 1 diabetes.
American City Business Journals
vTv Therapeutics appoints Paul Sehkri as new president and CEO
Following several leadership changes, High Point clinical stage pharmaceutical company vTv therapeutics Inc. has named Paul Sekhri as president and chief executive officer. He joins the company as it prepares to enter Phase 3 trials for its orally delivered Type 1 Diabetes treatment.